Here's what the FDA actually did: it granted marketing granted orders (MGOs) for three products within the JUUL2 system — the device itself, a Virginia Tobacco pod, and a Polar Menthol pod. Both pods contain 18 mg/mL of nicotine, equivalent to roughly 1.5–1.6% concentration. This is notably lower than the 5% (59 mg/mL) concentration that made the original JUUL controversial.
An MGO means JUUL Labs can legally market and sell these specific products in the United States. It does not mean the FDA has declared them "safe" or "FDA-approved." It means the agency determined that, on balance, the products are "appropriate for the protection of the public health" — the statutory standard under the Family Smoking Prevention and Tobacco Control Act.
The FDA's reasoning rested on three pillars:
- Adult switching: A substantial proportion of adult smokers completely switched from combustible cigarettes to JUUL2 products within six weeks. The menthol pod outperformed the tobacco pod.
- Reduced exposure: Adults who switched completely were exposed to lower levels of harmful chemicals than if they had continued smoking.
- Benefit-risk balance: For the menthol product specifically, FDA concluded the added benefit to adult smokers was sufficient to outweigh the risks, including youth appeal.
The menthol determination is the headline. Menthol has historically faced a steeper regulatory climb than tobacco flavor in the PMTA process. By explicitly weighing the higher switching rate against youth appeal — and siding with adult benefit — the FDA has set a precedent that other manufacturers will inevitably cite in their own flavor applications.
